Biotech RadarJobs updated

COMPANY

Inhibikase Therapeutics

HQ: Wilmington, DE source · inhibikase.com ↗ · Mid-Atlantic

Clinical Phase 3

Keywords: small molecule respiratory pulmonary arterial hypertension CML IKT-001 IkT-001Pro

Location: Wilmington, DE · source · Oct 15, 2026

Profile checked Oct 10, 2026

$375.0MRaised (2 yrs)4Trials (company is sponsor)

Timeline

  1. Trial start Phase 3: Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH) source ↗
  2. Trial start Phase 3: An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH) source ↗
  3. Raise Follow-on offering: $100M (total, as published), announced Nov 21, 2025. Source: company release on GlobeNewswire. source ↗
  4. Trial start 2: A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH) source ↗
  5. Raise Private placement: $275M (up to, as announced), announced Oct 21, 2024. Source: SEC filing. source ↗
  6. Trial start Phase 1: A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mg source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $375.0M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT07365332An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)Phase 3RecruitingApr 23, 20262029-06 (estimated)
NCT07632898Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)Phase 3Not yet recruitingOct 23, 2026Jun 30, 2030 (estimated)
NCT05623774A Dose Calibration Study Comparing IkT-001Pro to Imatinib Mesylate 400mgPhase 1CompletedDec 16, 2022Jun 30, 2024 (actual)
NCT06643143A Phase 2 Study of IkT-001Pro in Pulmonary Arterial Hypertension (PAH)2WithdrawnJun 30, 2025Jun 30, 2027 (estimated)
Feedback